Lipid nanoparticle-based delivery systems

Many modern drugs, despite their effectiveness, face significant limitations. Some have poor water solubility, which means that only a fraction of the active compound can be absorbed by the body. Many bioactive compounds are also prone to rapid degradation in the body due to enzymatic activity or changes in pH, reducing their therapeutic efficacy and potentially causing unwanted side effects.

In the search for the right balance between efficacy and safety, our attention has turned to lipid nanoparticles. Our team works with a broad range of lipid-based platforms, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and specialized lipid nanoparticles (LNPs) for nucleic acid delivery.

Unlike many synthetic polymeric or inorganic carriers, these systems are based on physiologically relevant, pharmacopeial-grade lipids. The natural compatibility of these components with the body gives the resulting nanoparticles a high level of biocompatibility.

An important focus of our work is the optimization of manufacturing processes. We aim to minimize or completely eliminate the use of toxic organic solvents, favoring safer approaches based on homogenization and self-assembly in aqueous media.

Ultimately, our research is focused on developing lipid-based delivery platforms that combine efficient encapsulation of modern therapeutic compounds with an excellent safety profile, paving the way for gentler and more effective treatment strategies.